Canaccord Genuity Maintains Buy on TriSalus Life Sciences, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic maintains a Buy rating on TriSalus Life Sciences (NASDAQ:TLSI) with a $12 price target.
June 27, 2024 | 1:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst William Plovanic maintains a Buy rating on TriSalus Life Sciences (NASDAQ:TLSI) with a $12 price target.
The reaffirmation of a Buy rating and a $12 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100